Lilly Expands LillyDirect Platform to Support Alzheimer's Disease Care

Eli Lilly and Company announced, that it has expanded its LillyDirect platform to improve access to Alzheimer’s disease care in the U.S. The enhancement includes tools that connect patients to independent in-person and telehealth providers, addressing long wait times and access issues—particularly in rural and underserved communities.

The new features do not include direct pharmacy services but instead focus on improving education and facilitating diagnosis and care coordination. Resources include Healthgrades, a doctor locator tool, and Synapticure, a specialized telehealth provider offering care navigation, neurology consultations within two weeks, and 24/7 support.

Lilly emphasized the importance of early diagnosis, noting that up to 3,000 Americans with Alzheimer's progress daily from mild to more severe stages, where treatment options are more limited. The company aims to empower patients to access timely and accurate care and plans to expand LillyDirect internationally.

Eli Lilly announced new data showing that Ebglyss (lebrikizumab-lbkz), a once-monthly biologic treatment for moderate-to-severe atopic dermatitis, achieved completely clear skin in 50% of patients and almost-clear skin in 87% of patients over three years. These findings come from the ADjoin long-term extension study and will be presented at the American Academy of Dermatology Annual Meeting.

Ebglyss is an interleukin-13 (IL-13) inhibitor that targets the primary cytokine involved in atopic dermatitis. The study included patients who initially responded to the treatment at Week 16 and continued with a maintenance dose of 250 mg every four weeks. More than 83% of these patients did not require additional topical corticosteroids or calcineurin inhibitors.

Additional studies showed significant improvements in itch, skin pain, and sleep loss due to itch, including in patients with skin of color and those previously treated with dupilumab. The safety profile remained consistent with prior clinical trials, with mild to moderate side effects such as conjunctivitis and injection-site reactions.

Ebglyss was approved in the U.S. in September 2024 as the first-line biologic treatment for moderate-to-severe atopic dermatitis in patients 12 years and older who do not respond to topical therapies. Lilly is working to expand insurance coverage through commercial, Medicaid, and Medicare plans to ensure broader patient access.